These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Lysis of herpes simplex virus-infected cells by lymphokine-activated killer cells. Chu CT; Lee P; Lin BJ; Sun MJ; Hsieh KH Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1991 Feb; 24(1):108-18. PubMed ID: 1657543 [TBL] [Abstract][Full Text] [Related]
23. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues. Colquhoun SD; Economou JS; Shau H; Golub SH J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167 [TBL] [Abstract][Full Text] [Related]
24. Induction of murine lymphokine-activated killer cells by recombinant IL-7. Lynch DH; Miller RE J Immunol; 1990 Sep; 145(6):1983-90. PubMed ID: 1975262 [TBL] [Abstract][Full Text] [Related]
25. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation. Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491 [TBL] [Abstract][Full Text] [Related]
26. Enhancement of murine lymphokine-activated killer cell activity by retinoic acid. Lin TH; Chu TM Cancer Res; 1990 May; 50(10):3013-8. PubMed ID: 1970751 [TBL] [Abstract][Full Text] [Related]
27. Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors. Mitchell DH; Withrow SJ; Johnston MR; Kruse CA Am J Vet Res; 1991 Jul; 52(7):1132-6. PubMed ID: 1892269 [TBL] [Abstract][Full Text] [Related]
28. Mouse tumors are heterogeneous in their susceptibility to syngeneic lymphokine-activated killer cells and delineate functional subsets in such effectors. Sensi M; Grazioli L; Rodolfo M; Parmiani G Cancer Immunol Immunother; 1990; 31(1):37-43. PubMed ID: 2306754 [TBL] [Abstract][Full Text] [Related]
29. [The in vitro antitumor effectiveness of murine lymphokine-activated killer (LAK) cells induced by recombinant IL-2]. Okamoto Y; Shimizu K; Miyao Y; Ushio Y; Matsui Y; Hayakawa T; Tsuda N; Mogami H No To Shinkei; 1986 Mar; 38(3):233-7. PubMed ID: 3486667 [TBL] [Abstract][Full Text] [Related]
30. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells. Holladay FP; Heitz T; Wood GW J Neurosurg; 1992 Nov; 77(5):757-62. PubMed ID: 1403119 [TBL] [Abstract][Full Text] [Related]
31. Infiltration patterns of short- and long-term cultured A-NK and T-LAK cells following adoptive immunotherapy. Kjaergaard J; Hokland M; Nannmark U; Hokland P; Basse P Scand J Immunol; 1998 Jun; 47(6):532-40. PubMed ID: 9652820 [TBL] [Abstract][Full Text] [Related]
33. Mechanism of exercise-induced augmentation of lymphokine activated killer (LAK) cell activity in the horse. Horohov DW; Keadle TL; Pourciau SS; Littlefield-Chabaud MA; Kamerling SG; Keowen ML; French DD; Melrose PA Vet Immunol Immunopathol; 1996 Oct; 53(3-4):221-33. PubMed ID: 8969043 [TBL] [Abstract][Full Text] [Related]
34. Sequential TNF and TGF-beta regulation of expansion and induction of cytotoxicity in long-term cultures of lymphokine-activated killer cells. Koberda J; Przepiorka D; Moser RP; Grimm EE Lymphokine Cytokine Res; 1994 Apr; 13(2):139-45. PubMed ID: 8061115 [TBL] [Abstract][Full Text] [Related]
35. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis. Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512 [TBL] [Abstract][Full Text] [Related]
36. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy. Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237 [TBL] [Abstract][Full Text] [Related]
37. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells. Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412 [TBL] [Abstract][Full Text] [Related]
38. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid. Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887 [TBL] [Abstract][Full Text] [Related]
39. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2. Tzeng JJ; Barth RF; Clendenon NR; Gordon WA Cancer Res; 1990 Jul; 50(14):4338-43. PubMed ID: 2364388 [TBL] [Abstract][Full Text] [Related]
40. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity. Vujanovic NL; Herberman RB; Hiserodt JC Cancer Res; 1988 Feb; 48(4):878-83. PubMed ID: 3257411 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]